BioNTech to pay $1.2 billion over vaccine royalties

Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
BioNTech Settles Royalty Dispute with NIH for $791.5 Million
BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, developed in collaboration with Pfizer.
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is trading at $114.25, up 0.42 percent on the Nasdaq.
COVID: BioNTech to pay $1.2 billion over vaccine royalties
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate disputes over royalty payments related to its COVID-19 vaccine.
BioNTech Settles Royalty Dispute with University of Pennsylvania
BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn,
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine royalty claims. Read more here.
BioNTech SE ADR falls Monday, underperforms market
BioNTech SE ADR closed $18.91 short of its 52-week high ($131.49), which the company achieved on September 17th.
ETF Daily News6d
BioNTech SE (NASDAQ:BNTX) Shares Sold by Tidal Investments LLC
Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, ...
Strategic Combinations Propel BioNTech’s B7-H3 ADC BNT324 Amidst Competitive Landscape: Analyst ‘Buy’ Rating
In a report released on December 6, Daina Graybosch from Leerink Partners maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
Brokerages Set BioNTech SE (NASDAQ:BNTX) Price Target at $140.76
BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...
Morningstar3d
BioNTech SE ADR BNTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Pharmaceutical Technology4h
BNT-321 by BioNTech for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.